Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1994 3
1995 4
1996 2
1997 1
1998 1
1999 1
2000 1
2002 4
2003 4
2004 1
2005 1
2006 1
2007 2
2008 3
2009 4
2010 5
2011 17
2012 13
2013 14
2014 5
2015 9
2016 11
2017 18
2018 14
2019 7
2020 12
2021 13
2022 23
2023 19
2024 21
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Results by year

Filters applied: . Clear all
Page 1
Emerging Targets in Non-Small Cell Lung Cancer.
Liu L, Soler J, Reckamp KL, Sankar K. Liu L, et al. Among authors: sankar k. Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046. Int J Mol Sci. 2024. PMID: 39337530 Free PMC article. Review.
Recent advances in the management of hepatocellular carcinoma.
Sankar K, Gong J, Osipov A, Miles SA, Kosari K, Nissen NN, Hendifar AE, Koltsova EK, Yang JD. Sankar K, et al. Clin Mol Hepatol. 2024 Jan;30(1):1-15. doi: 10.3350/cmh.2023.0125. Epub 2023 Jul 21. Clin Mol Hepatol. 2024. PMID: 37482076 Free PMC article. Review.
Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy.
Li G, Choi JE, Kryczek I, Sun Y, Liao P, Li S, Wei S, Grove S, Vatan L, Nelson R, Schaefer G, Allen SG, Sankar K, Fecher LA, Mendiratta-Lala M, Frankel TL, Qin A, Waninger JJ, Tezel A, Alva A, Lao CD, Ramnath N, Cieslik M, Harms PW, Green MD, Chinnaiyan AM, Zou W. Li G, et al. Among authors: sankar k. Cancer Cell. 2023 Feb 13;41(2):304-322.e7. doi: 10.1016/j.ccell.2022.12.008. Epub 2023 Jan 12. Cancer Cell. 2023. PMID: 36638784 Free PMC article.
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Gerstein HC, et al. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28. N Engl J Med. 2021. PMID: 34215025 Free article. Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Nassar AH, et al. Among authors: sankar k. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. J Thorac Oncol. 2024. PMID: 38278303 Free article.
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.
Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Nassar AH, et al. Among authors: sankar k. Nat Commun. 2025 Aug 19;16(1):7717. doi: 10.1038/s41467-025-63091-0. Nat Commun. 2025. PMID: 40830141 Free PMC article.
CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer.
Thiruvalluvan M, Billet S, Liu Z, Lownik J, Waissengrin B, Kim H, Villamejor AL, Milshteyn L, Li X, Gayhart M, Araña M, Sankar K, Posadas EM, Lopategui J, You S, Reckamp KL, Bhowmick NA. Thiruvalluvan M, et al. Among authors: sankar k. Drug Resist Updat. 2025 Jul;81:101237. doi: 10.1016/j.drup.2025.101237. Epub 2025 Mar 12. Drug Resist Updat. 2025. PMID: 40090182 Free article.
Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System.
Miller SR, Schipper M, Fritsche LG, Jiang R, Strohbehn G, Ötleş E, McMahon BH, Crivelli S, Zamora-Resendiz R, Ramnath N, Yoo S, Dai X, Sankar K, Edwards DM, Allen SG, Green MD, Bryant AK. Miller SR, et al. Among authors: sankar k. Cancer Med. 2024 Nov;13(21):e70379. doi: 10.1002/cam4.70379. Cancer Med. 2024. PMID: 39508134 Free PMC article.
230 results